Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma

Zundler S, Vitali F, Kharboutli S, Völkl S, Polifka I, Mackensen A, Atreya R, Neurath M, Mougiakakos D (2023)


Publication Type: Journal article

Publication year: 2023

Journal

Book Volume: 13

Article Number: 1149450

DOI: 10.3389/fonc.2023.1149450

Abstract

Chimeric antigen receptor (CAR) T cell therapy has become a new mainstay in the treatment of several hematologic malignancies, but the spectrum of associated complications is still incompletely defined. Here, we report the case of a 70-year-old female patient treated with tisagenlecleucel for diffuse large B cell lymphoma (DLBCL), who developed chronic diarrhea with characteristics of inflammatory bowel disease (IBD)-like colitis. CAR T cells were substantially enriched in the colon lamina propria and other diagnoses were ruled out. Thus, we conclude that IBD-like colitis in this patient was associated to CAR T cell therapy and needs to be considered as a rare potential complication.

Authors with CRIS profile

How to cite

APA:

Zundler, S., Vitali, F., Kharboutli, S., Völkl, S., Polifka, I., Mackensen, A.,... Mougiakakos, D. (2023). Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1149450

MLA:

Zundler, Sebastian, et al. "Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma." Frontiers in Oncology 13 (2023).

BibTeX: Download